Clinical Trial Detail

NCT ID NCT02332668
Title A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Hodgkin's lymphoma

lymphoma

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: child

No variant requirements are available.